A B S T R A C T Sheep red blood cells can surround, in vitro, some human peripheral blood lymphocytes in a formation called a rosette. The number of rosetteforming cells (RFC) in 50 normal persons had a wide range (4-40%).
INTRODUCTION
The adherence of sheep red blood cells (SRBC)' to a lymphocyte results in a formation termed a rosette (1) (2) (3) (4) . Rosettes are formed by a small percentage of lymphocytes from peripheral blood of normal nonimmunized people. The significance of rosette formation in man is not well understood. Its role as an immunological tool is still controversial, although inhibition of the normal rosette formation by anti-lymphocyte serum (ALS) has been shown to be a very sensitive index of the immunosuppressive activity of various ALS preparations (1) . In order to obtain information on this phenomenon and to investigate its significance, the present study was conducted in human fetuses.
METHODS

Materials
Fetal tissuies. Fetuses were obtained at time of abdominal hysterotomies for therapeutic abortions and processed immediately. Fetal age was derived from the measurement in millimeters of crown-rump length, in accordance with data of the Carnegie embryological collection (5) .
Thymus, spleen, and liver were obtained by sharp dissection, minced, and homogenized.! The homogenates were passed through fiberglass wool contained in a syringe, resulting in a single cell suspension for each organ. Bone marrow was obtained by flushing the epiphyseal ends of long bones with a syringe and a small-gauge needle. All cells were washed three times in phosphate-buffered saline (PBS, pH 7.3).
Blood. Blood was obtained from 50 lnormal humani subjects (18 months to 81 yr old) and from 8 patients with immunological disorders. This group was composed of three patients with acquired liypogammaglobulinemia, four with 'Abbrez'iations ulsed int this papcr: ALS, anti-lymphocyte serum; FT-RFC, fetal thymic rosette-forming cells; PBS, phosphate-buffered saline; PHA, phytohemagglutinin; PPD, purified protein derivative; RFC, rosette-forming cells; SRBC, sheep red blood cells; T.F., transfer factor.
2 Potter-Elvehjem tissue grinder, Kontes Glass Co., Vineland, N. J. (6) . The lymphocytes were washed three times in 10 ml of PBS (pH 7.3) and their concentration was adjusted to 5 X 106/ml. Except in the fetal blood, the ABO group and the titer of hemagglutinating antibodies against SRBC were determined. Antisera. Antisera were prepared in goats and rabbits. Pure heavy-chain or light-chain proteins were isolated from myeloma proteins or Bence Jones proteins by precipitation with Na2SO, and fractionation in a DEAE column.
The antisera were rendered monospecific by successive absorptions with aggregates of the appropriate types of heavyand light-chains cross-linked with glutaraldehyde (7) . The antisera were heat inactivated at 56°C for 30 min and absorbed with SRBC and human red blood cells, twice at 37°C and twice at 4°C. No agglutination of red cells was detected after these procedures. Specificity was determined by gel diffusion and by the more sensitive CrC13 hemagglutination inhibition method (8) . The following titers, assessed by the latter method, were obtained: goat anti-a, 1: 600,000; rabbit anti--y, 1: 600,000; goat anti-/A, 1: 600,000; rabbit anti-K, 1: 640; and rabbit anti-X, 1: 2560.
Horse antiserum to human e-chain was purchased from Kallestad Laboratories; ' it was processed the same way as the antisera prepared in our laboratory (heat inactivation, immunoadsorption, and absorption on red cells). 
Experimental Procedures
The method of rosette formation was based onI the technique described by Bach, Dormont, Dardenne, and Balner (1) . In each test, 0.05 ml of the lymphocyte suspension was used. In the inhibition studies, lymphocytes were incubated at 37°C with 0.05 ml of antiserum (undiluted or diluted in saline) for 1 hr before addition of SRBC. Control specimens were incubated in PBS for 1 hr at 37°C. SRBC were added to obtain a finial ratio of eight SRBC for every lymphocyte. The fewer RFC found in later weeks. RFC of the oldest fetuses tended to be in clusters. Fetal blood. Only a small percentage of RFC was found in the fetal blood lymphocytes studied. These RFC were completely surrounded by the SRBC except in fetuses 1 and 5.
Fetal spleen. The RFC appeared at around 13-14 conceptual wk of age. Since no RFC were found in fetuses 2, 3, and 4 after counting twice 4000 cells, the difference between this group and the oldest fetuses (where 0.5% of RFC was found after counting twice 500 cells) is statistically significant (P <0.001 by Poisson approximation).
Fetal liver. RFC were found in 2 of the 10 specimens studied. The number of RFC was small in both specimens, each of which was derived from 17-to 18-wk fetuses.
Fetal bone marrow. For technical reasons, only six bone marrows were examined. The bone marrow of fetus 11 had many red cells, which may suggest some blood contamination. Specimens from the other fetuses were relatively poor in red blood cells and probably represented a pure marrow sample. In these, very few or no RFC were found.
Blood. Normal subjects. The peripheral blood lymphocytes of 50 normal individuals had a mean of 12% RFC with a range of 4-40% (Table II) . On repeated examinations in any one individual, the percentage of RFC was found to vary approximately 25% about that person's mean. A slight decrease in the number of RFC was noted after 60 min of incubation at 37°C. The results are given after this period of time because, in the studies done with antisera, incubation lasted 1 hr; 12, 9 and 5% of blood RFC. Four patients with Wiskott-Aldrich syndrome showed respectively 1, 1, 1.5, and 1% of blood RFC. One patient with Nezelof syndrome showed a complete absence of RFC in the peripheral blood (Table III) .
Effect of the different antisera on rosette formation Fetus. Lymphocytes from fetal thymus were studied with undiluted antisera because of the small number of fetal cells available. There was a constant inhibition of rosette formation with antiserum to y-chains. (Table   IV ). The inhibition with antiserum to /u-chain became significant between 13 and 14 wk. Inhibition with antia-chain was interpreted as not meaningful, since it was within the range of the error of the method. Only fetus 2 showed an inhibition with anti-K-and anti-X-chain sera, while fetus 8 had a significant decrease of RFC with anti-K-chain serum and fetus 12 with anti-X-chain serum. Lymphocytes from the peripheral blood, spleen, and liver of fetuses 5, 8, 11, and 13 were studied, and complete inhibition was found with anti--y-or anti-iLchain sera only. The other antisera had no inhibitory effect. The effect of the antisera was not studied in the fetal bone marrow because of the small number of these cells.
Adults. Rosette formation by cells from normal adults was always completely inhibited by undiluted
The Human Rosette as a Marker of Thymus-Derived Cells 2-03t antisera to both y-and AL-chains (Table II) . Anti-K and anti-X, as well as anti-a and anti-e, varied in their effects. In the few patients in whom anti-e produced marked inhibition of rosette formation, no allergic background was fotund. With diluted antisera, the inhibition of the rosette formation was gradually decreased and with dilutions higher than 1: 40, inhibition with anti-e and anti-A was completely abolished.
Three patients with acquired hypogammaglobulinemia were studied. They responded differently from normal controls in that the inhibition of rosette formation with undiluted antisera to y-and IL-chains was not always complete (Table III) . DISCUSSION Rosette-forming cells were found in all thiyimocvte saiples tested. The lowest numbers of fetal thymic RFC (FT-RFC) were found in the youngest fetus (11 wk) and in fetus 5.' At around the 15th wk, up to 65% of fetal thymocytes had the ability to bind to SRBC. This gestational period may be significant in view of the observation by Papiernik that maximal PHA stimulation of fetal thymocytes also occurs at this time (9) .
Lymphocytes with the ability to bind to SRBC appear to be, at the gestational ages studied, chiefly present in the thymus. However, there were always thymocytes free of SRBC suggesting that this property may be characteristic of only some population (s) of thymic cells. In contrast, the percentage of RFC outside the thymus was low, except in fetus 11, 18 wk of age, which showed a marked percentage of RFC outside the thymus associated with the lowest percentage of FT-RFC found around this period.
The apparent decrease of FT-RFC in the elder fetuses may be purely explained on the basis of morphological changes in the thymus, that is, enlargement of the cortical area (9) . Migration of the RFC outside the thymus is an alternate explanation for this decrease. This latter hypothesis would be consistent with the slight increase in the blood and spleen RFC of the elder fetuses. However, the number of fetuses studied is too small to draw any definite conclusions in this regard, anid other possibilities such as the maturationi of receptors for SRBC or the presence of a thymic horimionie, slhould also be coinsidered to explaini the appearance of the blood RFC.
Six specimenis of bone marrow were studied and, except for fetus 11, the percentage of RFC was always 5Fetus 5 showed an abnormal pattern when compared to fetuses of the same gestational age: each FT-RFC had only three to four SRBC clinging to it, and its thymocytes had a low response to PHA for this period of gestation. (Stites, D. P., M. C. Carr, and H. H. Fudenberg. Unpublished observation.) very low whlen compared to the number of FT-RFC. Overall, the absolute numbers of lymphoid-like cells recoverable from the thymus were at least 10-fold those recoverable from the bone marrov in the age range of the fetuses studied.6 Therefore, if RFC are formed in the bone marrow, their nunmber would probably be extremely small compared to the thymus, although a very high turnover rate could conceivably allow the marrow to be the source. The fetal spleen and liver are thought to be the site of origin of stem cells (10, 11) . The finding of blood RFC in the youngest fetuses when Ino RFC were found in the spleen or in the liver of the same fetuses makes it very unlikely that these organs serve as the direct source of the blood RFC at this period of gestation.
These observations suggested to us that the property of spontaneous rosette formation by the blood lymphocvtes mav be chiefly one of thymic-derived cells.
To support this hypothesis, patients with immunological disorders were studied. The group with humoral deficiency included three patients with acquired hypogammaglobulinemia whlo showed a percentage of RFC in the normal range. In contrast, patients with impairment or absence of cellular immunity showed a decrease or absence of blood RFC. The four patients with WTiskott-Aldrich syndrome showed a low number of blood RFC and an impairment of their cellular immunity as tested by classical parameters (phytolhenagglutinin response, production of migration inhibitory factor, and skin tests). One patient wvith Nezelof syndrome, a disease characterized by an hypoplasia of the thymus and a complete lack of cellular immunity, had Ino blood RFC (12) . Furthermore, when patients w-ith Wiskott-Aldrich syndrome were treated with transfer factor (T. F.), only the ones who responded to this treatment by the conversion of skin tests, the production of migration inhibitory factor, and bv freedom of infections showed an increase (from 1 to 7 or 8%) in their blood RFC. In contrast, one patient did not respond to T. F. by clinical and laboratory parameters and did not increase his number of blood RFC. 7 These findings suggest that blood RFC are related to the status of cell-mediated immunity which is considered to be a thvmuus-depenidenit ftuniction. Two indirect ar-gumiients in favor of the RFC being thyviius derived shlouild also be mentionledl. Namnely tllat rosette inhibitioni by ALS inl vitro coirrelates verv well wvith ALSinduced delay in skini graft rejection (1) phocytes cultured with PPD, in presence of antisera to human immunoglobulins (the response to PPD is mainly a T-cell function) (13) .
For all these reasons, it is suggested that the blood RFC is likely to be mainly thymus derived and therefore can be considered as a marker of some population (s) of thymus-derived cells in humans.
In mice the RFC has been extensively studied. It has been shown by numerous authors that some RFC may bear the theta antigen, a marker of thymus-derived cells (14) . RFC in nonimmunized mice are involved in antigen recognition and can originate in both thymus and bone marrow (15) (16) (17) (18) (19) (20) (21) . However, the percentage of RFC in man is at least 100-fold that found in the mouse (21) and the phenomenon of human rosette formation perhaps involves mechanisms other than those in the mouse. In the guinea pig, macrophages and homologous or autologous thymocytes adhere together without the participation of any known action of antibodies (22) . This property of adhesiveness may be unique to the thymic cell and relevant to the high number of RFC found in the human fetal thymus. Some other nonimmunological mechanisms (e.g. incubation of lymphocytes at 4°C increases the number of adult human RFC) may be involved in human rosette formation (3, 4) .
Another aspect of our findings deals with the inhibition of RFC by antisera to heavy-chains, raising the possibility of the presence of heavy-chain determinants on thymic cells. The validity of these inhibition studies depends upon the specificity of the antisera used and also on the knowledge of the basic mechanisms involved in the human rosette formation. Monospecificity was carefully checked by hemagglutination inhibition. The existence of heteroantibodies is unlikely since these antisera were neither agglutinating nor cytotoxic, in the presence of complement, against a panel of human leukocytes. The finding of increasing inhibition on FT-RFC by goat anti-I serum argues for the specificity of this antiserum. Indeed, the absence of inhibition with anti-a serum, which was produced in the same species as anti-,a, gives an internal control. Furthermore, if this antiserum was acting nonspecifically, one might not expect the gradual pattern of inhibition seen here, but rather a random, total, or absent inhibition.
The inhibition with anti-e serum introduces the possibility that y-chain determinants are present on these cells. However, the inhibition with anti-y serum was always present in FT-RFC which may suggest nonspecific mechanisms. This validity of these results has already been discussed. This observation introduces the possibility that 'v-chain determinant is also on the thymus cells. The origin of this 'v-chain determinant may be maternal since IgG of maternal origin is detected in the serum of early stage fetuses (25) . However, a fetal origin is not excluded for these '-chain determinants. In contrast, no significant inhibition of rosette formation occurred with anti-a serum. This is consistent with the current evidence that IgA does not cross the placenta and is not synthesized by the human fetus at this stage. The effect of the antisera to light-chains was variable, per-haps because of the relatively weak titer of these antisera or because bturied determinants of light-chains exist on the lymphocyte surface.
Using various methods, most investigators (26-32) have found heavy-chains on B-cells which are presumably bone marrow-derived in mammals and involved in humoral immunity (23) . On the other hand, few or nio heavy-chains wvere detected on thymocytes. Yet recenit sttudies suggest the possibility that miiouse and human thymocytes and T-cells may possess /-chain or L-chain-like determinants on their surfaces (33-36).8
One of these studies reports the isolation of A-chains with a molecular weight of 200,000 from human and mouse thymuses (36) . In none of these studies was ,y-chains detected.
In conclusion, the study of rosette formation in the lymphoid tissues of 11-to 19-wk human fetuses suggested that spontaneous RFC imiay be chiefly thymus serum. The possibility of y-chain on these cells has been raised. Finally, it is proposed that human blood RFC may be considered as a marker of a substantial population of thymus-derived cells and that the study of these RFC is a valid tool in assessing patients with immunological disorders.
